Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNLI · against 329 other Healthcare companies of similar size
Ranked #245 of 330 · scores higher than 4% of peers
Bars: peers in each 10-point band of the valuation score86 peers with a valuation score of 0–9, including DNLI · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | DNLI | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 324 reported | -14.6% | 2.3% | 9% | 30% | |
| EBITDA yieldHigher is better · 324 reported | -21.6% | 4.6% | 2% | 50% | |
| Free cash flow yieldHigher is better · 174 reported | -15.0% | -0.2% | 5% | 20% | |
| Book yieldHigher is better · 322 reported | 26.9% | 29.6% | 46% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 245 | 5.7B USD | 8 | 52 | |
| 245 | 2.3B USD | 8 | 25 | |
| 245 | 5.4B USD | 8 | 38 | |
| 245 | 4.8B USD | 8 | 27 | |
| 245 | 3.1B USD | 8 | 27 | |
| 245 | 4.6B USD | 8 | 29 | |
| 245 | 3.4B USD | 8 | 35 | |
| 245 | 3.3B USD | 8 | 44 | |
| 245 | 5.1B USD | 8 | 35 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score